Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. - Wikidata - wikimedia - TriplyDB

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

http://www.wikidata.org/entity/Q33872754

about

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies Update on rational targeted therapy in AML Discovery of new anticancer agents from higher plants Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Minimal residual disease in acute myeloid leukaemia Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.Targeting cell cycle regulators in hematologic malignancies.Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia CDK9 and its repressor LARP7 modulate cardiomyocyte proliferation and response to injury in the zebrafish heart A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Development of therapeutic agents for older patients with acute myelogenous leukemia.Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.Acute myeloid leukaemia: optimal management and recent developments.Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes Exploiting cellular pathways to develop new treatment strategies for AML.Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Acute myeloid leukemia: focus on novel therapeutic strategies.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?New treatment for acute myelogenous leukemia.Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia.c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.The rocky road to personalized medicine in acute myeloid leukaemia.CDK9 inhibitors in acute myeloid leukemia.Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies

P2860

Q24561485-98FD1171-F869-40BB-B660-B9A91E9C541B Q26766152-161BDBBF-E9E5-4FE5-91F4-BD8E1490C404 Q27006814-A95F6FEF-C17C-46C8-BFFF-268FC587C6E0 Q28972291-F9BE2F7B-99F9-407B-9B19-C6E7AA9066A3 Q34179265-F31580D0-C1E3-4714-9AC6-98C29617C986 Q34754350-09FA5D36-749E-44F2-AE1A-8D5C92DA8F97 Q35334436-BF478D48-7644-4F5A-BF83-AD4001032D09 Q35545492-7F1810EF-7D68-46C8-A6BC-0C948B2ED5E1 Q35651754-B50A61EF-9B80-40A8-95BF-4FA349670F7F Q35834044-0DA892F7-5CB7-40C2-84BC-8776AC4E6E1D Q35885317-8742D886-B372-4888-8E62-28AFAC37A499 Q36002546-630055FC-F320-4D9C-9478-B2ED99615592 Q36366636-F0275E16-83D7-44B5-95DF-692035D68D9A Q36424315-C546C600-95C0-490E-A7A0-3919E833F6DF Q36709001-85734922-91AB-4C02-BA4B-7A98E89DFF98 Q36914091-5834F819-5AAC-416F-B184-37DDBE57F9F8 Q37104378-71D59DE3-1675-4C23-B483-45354DF34F41 Q37199802-7473BCEC-9556-4C57-948F-040496C28EFD Q37216232-37A67BDD-A612-47F5-9037-4EA2F26F108B Q37670417-07447195-2436-436F-B78A-080E1D345778 Q37701894-11EE8C1D-0F37-434C-9449-D0D376D22596 Q37790694-7404FEB2-BCE1-4C9D-9F84-0173F6993629 Q37842861-9550FB16-929B-48DE-A2C7-F4DD5D657189 Q37866341-E981324B-A6A5-42F2-80D5-3821DE7205FE Q38015336-1626A329-F923-4286-B7D4-6138745A5673 Q38103753-0C366E7B-AFD0-43DF-B20A-0BE2E285E3AC Q38284045-C41DE7F9-359E-4A6A-920C-4D38DF468EDD Q38693748-B7E6B378-53EC-48EB-86A3-332900B80C68 Q38973410-A466A6F7-9CED-42C8-9811-5A6F3B0E3B8F Q42943359-AAFAB0C5-AB83-4E18-BEB8-BE7536FEDB31 Q43487946-98621FCF-25A5-4967-B4F3-7C4BB67E0125 Q47561008-09D7C11F-26F3-4D6B-9D89-32277489F1EA Q50318294-3F9787F3-54A2-4BCD-8769-ED05CFB18FE1 Q58585587-79BEAA23-C3EF-4EEC-97AF-CBA4F93DCE0B

P2860

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

http://www.wikidata.org/entity/Q33872754

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@ast

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@en

type

label

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@ast

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@en

prefLabel

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@ast

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@en

P1433

Q33872754-C8157D9A-B1C1-4573-B18D-54E2D07DC9D1

P1476

Q33872754-736AC982-2E28-473D-A44E-D9D29338E23D

P2093

Q33872754-11E73B7B-AD26-4695-A2AA-8AF7CE54FE03

Q33872754-1D3DE1F8-332D-4251-9D00-4822F7B7CF04

Q33872754-1E7193DC-750F-43F0-AD5A-535E8F6C0362

Q33872754-3CAAAC1F-CAAE-4EF0-A1E1-A5ADBCF12339

Q33872754-4B385E7A-8E30-47F9-B0A1-69BC128A1626

Q33872754-4CA66115-DE87-4439-88ED-75D7BF570D73

Q33872754-4D2AE52E-8203-4C50-8D07-FC5BDFABB6ED

Q33872754-6BA95731-AE81-49B8-AA38-4B54AA39D65A

Q33872754-731DD74A-7131-4EEA-8161-3EFFE8CE7CC7

Q33872754-78B4190C-0ACD-4777-8D34-E6B23EF8CBA3

P2860

Q33872754-17F8AAB8-B6FC-485B-93CA-F4EB91DD78D0

Q33872754-30184E99-BC21-430A-A80D-C1EFD37AAA22

Q33872754-38B89584-2F95-41C0-9001-80911E59A7E8

Q33872754-3FEBEFA4-D8F2-420F-BEA1-2C1994CA5831

Q33872754-417108A6-072A-40EF-BA9B-BD2D618F9C74

Q33872754-4424159F-3139-4727-BDA8-DFC6FA31DF5F

Q33872754-4A12EE80-82DF-4897-A1E8-8E160F4A57A0

Q33872754-4B67F166-6C97-417E-9455-957DB4A1C391

Q33872754-4BB8564D-B13A-4322-AD91-A2E0AC8A8155

Q33872754-508703E5-621D-46B0-9770-16018C7EB766

P304

Q33872754-05CE3F6E-DBB8-42A2-9C09-0D9B541D262E

P31

Q33872754-0D37B35C-8181-47FE-8889-C5612091CD1B

P356

Q33872754-AA1AD9B6-D0D7-47AD-9657-C83EC444BBC7

P433

Q33872754-20A381D7-FC82-4975-8D5A-2F15CF9FAFC0

P478

Q33872754-BB9AB27D-6D16-43F3-B9A6-2A51135806DD

P577

Q33872754-96A8BCA7-B365-4959-84A3-27DD46E9102E

P5875

Q33872754-79F769EB-2D30-4D75-A500-31B4260A9E20

P698

Q33872754-C50C3A6D-84DF-42D5-9C38-C7773926FC53

P921

Q33872754-BB863164-B75C-493A-ABE7-2624916D5E1E

P932

Q33872754-6B339469-153D-43DC-B382-32F0053942F4

P356

J.LEUKRES.2009.11.007

P1433

Leukemia Research

P1476

Clinical activity of sequentia ...... sk acute myelogenous leukemia.

@en

P2093

Amanda Blackford

http://www.w3.org/2001/XMLSchema#string

Amy Hatfield Seung

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Hetty E Carraway

http://www.w3.org/2001/XMLSchema#string

Jacqueline M Greer

http://www.w3.org/2001/XMLSchema#string

Javier Bolaños-Meade

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

Katrina Alino

http://www.w3.org/2001/XMLSchema#string

L Austin Doyle

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Preclinical and clinical development of cyclin-dependent kinase modulators.

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.

Age and acute myeloid leukemia.

High-dose daunorubicin in older patients with acute myeloid leukemia.

Anthracycline dose intensification in acute myeloid leukemia.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Acute myeloid leukemia and myelodysplastic syndromes in older patients.

P304

877-882

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2009.11.007

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40449739

http://www.w3.org/2001/XMLSchema#string

P698

19962759

http://www.w3.org/2001/XMLSchema#string

P921

P932

2875369

http://www.w3.org/2001/XMLSchema#string